Stage Determines Everything
The CSO a Series A biotech needs is a fundamentally different person from the CSO a commercial-stage biotech needs.
At Series A, the CSO is the science. They are designing experiments, interpreting data, presenting to investors, and often managing fewer than 10 people. At commercial stage, the CSO is managing a scientific organisation of potentially hundreds, setting research strategy across multiple programmes, and spending significant time on investor relations and board management.
Hiring a commercial-stage CSO for a Series A company wastes money. Hiring a Series A CSO for a commercial-stage company creates chaos.
The Board Dynamic
CSO searches are uniquely influenced by board composition. If the board includes scientific co-founders or investor directors with deep domain expertise, the CSO must hold their own in rigorous debate while translating science into business outcomes. If the board is primarily financial, the CSO must be comfortable as the sole scientific authority in the room.
Compensation at the Top
CSO compensation in US biotechs ranges from $300,000 to $450,000 base with total compensation of $500,000 to $1.2M+ when equity is included. The equity component dominates at earlier-stage companies: a Series A CSO might accept a lower base in exchange for 1-3% equity.
Assessment Beyond Publications
Publication record and academic pedigree are necessary but not sufficient. Three questions reveal whether a candidate can lead science, not just do it:
1. Describe a programme you killed and why. The willingness to terminate a scientifically interesting but commercially unviable programme is the hallmark of a strategic scientific leader.
2. How have you managed a disagreement with your CEO or board about scientific direction? This reveals whether the candidate can defend scientific rigour while respecting commercial realities.
3. What is the most important hire you have made and why? This reveals whether the candidate builds teams or hoards expertise.